2,2-dibromo-3-nitrilopropionamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 25059 |
| CHEMBL ID | 1878278 |
| SCHEMBL ID | 23129 |
| MeSH ID | M0050447 |
| Synonym |
|---|
| AKOS015833850 |
| caswell no. 287aa |
| acetamide, 2,2-dibromo-2-cyano- |
| xd 7287l |
| hsdb 6982 |
| einecs 233-539-7 |
| epa pesticide chemical code 101801 |
| brn 1761192 |
| acetamide, 2-cyano-2,2-dibromo- |
| nsc 98283 |
| 10222-01-2 |
| 2,2-dibromo-3-nitrilopropionamide |
| nsc98283 |
| nsc-98283 |
| 2,2-dibromo-2-carbamoylacetonitrile |
| xd-7287l antimicrobial |
| xd-1603 |
| acetamide,2-dibromo-2-cyano- |
| dbnpa |
| 2,2-dibromo-2-cyanoacetamide |
| dibromocyanoacetamide |
| 2,2-dibromo-2-cyanoacetamide, 96% |
| NCGC00164203-01 |
| NCIOPEN2_006184 |
| 2,2-dibromo-2-cyano-acetamide |
| 2-cyano-2,2-dibromoacetamide |
| D2902 |
| A800546 |
| 2,2-bis(bromanyl)-2-cyano-ethanamide |
| NCGC00164203-02 |
| 3-02-00-01641 (beilstein handbook reference) |
| unii-7n51qgl6mj |
| 7n51qgl6mj , |
| dtxcid3012361 |
| NCGC00253921-01 |
| dtxsid5032361 , |
| tox21_300089 |
| cas-10222-01-2 |
| c3h2br2n2o |
| dibromonitrilopropionamide |
| dowicil qk 20 |
| dibromocyano acetic acid amide |
| 2,2-dibromo-3-nitrilopropanamide |
| FT-0612090 |
| dibromo-3-nitrilopropionamide, 2,2- |
| 2,2-dibromo-3-nitrilopropionamide [hsdb] |
| dow antimicrobial 7287 |
| dibromocyanoacetamide [inci] |
| SCHEMBL23129 |
| Q-102771 |
| CHEMBL1878278 |
| UUIVKBHZENILKB-UHFFFAOYSA-N |
| 2,2-dibromo-3-nitrilopropion amide |
| mfcd00129791 |
| 2,2-dibromo-2-cyanoacetamide, 9ci |
| 2, 2-dibromo-2-carbamoylacetonitrile |
| 2-cyano-2,2-dibromo-acetamide |
| cyanodibromoacetamide |
| Q5204411 |
| AS-12928 |
| 2,2-dibromo-3-nitrilo propionamide (dbnpa) |
| H11778 |
| dbnpa; 2,2-dibromo-2-cyanoacetamide; 2,2-dibromo-2-carbamoylacetonitrile; 2,2-dibromo-3-nitrilopropionamide; dbnpa |
| CS-0144768 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "50 mg/L) were the most toxic compounds tested and were detected at concentrations of 16 and 59 microg/L, respectively, in a closed-circuit recycling paper mill." | ( Bioluminescence inhibition assays for toxicity screening of wood extractives and biocides in paper mill process waters. Barceló, D; Lacorte, S; Latorre, A; Rigol, A, 2004) | 0.32 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 50.1187 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| AR protein | Homo sapiens (human) | Potency | 56.5103 | 0.0002 | 21.2231 | 8,912.5098 | AID588516; AID743042; AID743054 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 25.0575 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 4.8558 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 12.0293 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 76.9588 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 26.0482 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID588513; AID743079 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 44.6684 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 47.3935 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 15.3065 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743223 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 76.9588 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 39.1512 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 21.6899 | 0.0003 | 23.4451 | 159.6830 | AID743066 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 4.4668 | 24.8329 | 44.6684 | AID651749 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 37.9319 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 30.6379 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 79.4328 | 0.0023 | 19.5956 | 74.0614 | AID651743 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 30.6379 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (9.09%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||